Company patents
LONZA SALES AG
LONZA SALES AG's patent strategy is heavily concentrated in "Pharmaceutical Preparations," accounting for 82.0% of its portfolio, with a significant emerging focus on "Therapeutic Activity (Pharma)" which saw a 100.0% year-over-year growth in 2025, and "Bioreactors / Cell Culture Apparatus" which experienced a 200.0% year-over-year growth in 2025, indicating a strong commitment to core pharmaceutical development and related biotechnologies despite a partial decline across most categories so far in 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
50 US filings (since 2023) · 11 categories · 15 themes
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Methods and apparatus specifically tailored for the expansion, differentiation, or genetic modification of cells for therapeutic applications (e.g., CAR T cells, progenitor cells) or for the production of specific biological products (e.g., cultured fat, RNA).
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Development of food compositions, beverages, or powders designed to provide specific health benefits beyond basic nutrition, such as weight management, anti-aging, exercise support, or targeted disease prevention/treatment, often incorporating bioactive compounds or probiotics.
Systems and methods for accurately controlling the volume, location, and characteristics of sprayed fluids, often involving sensors, feedback, or specific nozzle geometries for precise application.
Spraying devices designed to handle, mix, or independently dispense multiple distinct fluid components, often with mechanisms for selection, blending, or sequential application.
Patents
Showing 1-4 of 4
Immune Checkpoint Modulation